Share This Page
Suppliers and packagers for lupkynis
✉ Email this page to a colleague
lupkynis
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Aurinia | LUPKYNIS | voclosporin | CAPSULE;ORAL | 213716 | NDA | Aurinia Pharma U.S., Inc. | 75626-001-02 | 3 PACKET in 1 CARTON (75626-001-02) / 4 BLISTER PACK in 1 PACKET (75626-001-01) / 15 CAPSULE in 1 BLISTER PACK | 2021-01-22 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: LUPKYNIS
Introduction
LUPKYNIS (voclosporin) is an immunosuppressive drug developed by Bristol-Myers Squibb for the treatment of active lupus nephritis, a severe manifestation of systemic lupus erythematosus (SLE). Since its FDA approval in January 2021, LUPKYNIS has gained prominence as a targeted therapy, necessitating a reliable supply chain of its key raw materials and active pharmaceutical ingredients (APIs). This article provides an in-depth analysis of the current supplier landscape for LUPKYNIS, examining manufacturing partners, raw material sources, regulatory considerations, and the strategic importance of secure supply chains in the pharmaceutical industry.
Manufacturing and Supply Chain of LUPKYNIS
LUPKYNIS's active component, voclosporin, is a calcineurin inhibitor structurally similar to cyclosporine but with enhanced potency and pharmacokinetic properties. Manufacturing of voclosporin is complex, involving multiple synthetic steps, strict quality controls, and stringent regulatory adherence, which collectively influence its supply chain dynamics.
Bristol-Myers Squibb (BMS) is the primary developer and manufacturer of LUPKYNIS, owning the proprietary rights to voclosporin's synthesis, formulation, and distribution. The company’s global manufacturing network plays a central role in ensuring drug availability across regions. However, in high-demand specialty drugs like LUPKYNIS, securing primary and secondary suppliers for raw materials and API precursors is vital to mitigate risks of supply disruption.
Key Raw Materials and APIs: Sources and Suppliers
Active Pharmaceutical Ingredient (API): Voclosporin
The synthesis of voclosporin involves several key chemical intermediates, with the final API requiring rigorous purity standards. The primary suppliers and manufacturing pathways for voclosporin include:
-
Bristol-Myers Squibb's internally integrated manufacturing facilities
BMS has invested in in-house production to safeguard critical API quality and supply consistency, particularly given early supply constraints experienced with biologics and complex small molecules in the industry. -
Contract Manufacturing Organizations (CMOs)
To scale production, BMS collaborates with external CMOs, often located in regions with advanced chemical synthesis capabilities such as India and China. These partnerships enable increased production capacity and help meet global demand.
Precursor and Intermediate Chemicals
The synthesis of voclosporin requires high-purity precursors, often sourced from specialized chemical suppliers. Some of these suppliers include:
- Global chemical companies such as Ashland Inc., BASF, and Dow Chemical, which provide intermediates essential for the synthesis pathway.
- Specialized biotech chemical suppliers catering to pharmaceutical-grade intermediates, often with stringent quality certifications (e.g., cGMP compliance).
Raw Material Considerations
- Supply Chain Complexity: The chemical synthesis pathway involves multiple steps, each with potential supply chain vulnerabilities, such as geopolitical risks or market concentration among a few suppliers.
- Regulatory Environment: Suppliers must meet rigorous standards from agencies like the FDA and EMA, including cGMP compliance, which influences sourcing choices.
- Sustainability and Ethical Sourcing: Increasingly, pharmaceutical companies scrutinize raw material provenance, emphasizing environmental sustainability and ethical sourcing practices.
Manufacturing Partners and Strategic Partnerships
While BMS primarily produces voclosporin through its own facilities, the complexity of synthesis and high demand have led to reliance on external partners:
-
CMO Collaborations:
BMS’s strategic alliances with CMOs facilitate scalable production. These organizations typically operate in regions with established pharmaceutical manufacturing infrastructure, such as India, which hosts several CDC (Contract Development and Manufacturing) organizations specializing in complex small molecules ([1]). -
Technology Transfer Agreements:
Ensuring quality and consistency involves transfer of proprietary synthesis technology to manufacturing sites globally, which BMS manages carefully under strict licensing agreements.
Regulatory and Compliance Factors
Suppliers of APIs and intermediates for LUPKYNIS must adhere to the strictest regulatory standards:
-
Current Good Manufacturing Practices (cGMP):
Ensuring quality, potency, and purity of voclosporin and its precursors. -
Single-Source vs. Multiple-Source Strategies:
To reduce supply risks, BMS aims to diversify its supplier base for critical materials, though the complexity of synthesis limits the proliferation of qualified suppliers in some cases. -
Supply Chain Transparency:
Regulatory agencies and market players increasingly demand visibility into raw material provenance, influencing supplier choices.
Supply Chain Risks and Mitigation Strategies
The supply chains for small-molecule drugs like LUPKYNIS are vulnerable to:
- Geopolitical disruptions: Trade tensions, tariffs, and export controls in key supplier countries.
- Raw material shortages: Fluctuations in availability of key chemical precursors.
- Quality control issues: Variability in supplier compliance with GMP standards.
- Manufacturing capacity constraints: Unexpected demand surges or production halts.
Mitigation measures include dual sourcing, strategic stockpiling, establishing regional manufacturing hubs, and active supplier qualification processes.
Emerging Trends and Future Outlook
The evolving landscape indicates a move toward vertical integration, with BMS increasing in-house manufacturing capacity for voclosporin to enhance supply security. Additionally, technological innovations such as continuous manufacturing and process intensification aim to streamline production, reduce costs, and enhance quality control.
Market demand for LUPKYNIS is projected to grow as awareness of lupus nephritis treatment options increases, compounded by expanding registries and clinical practice adoption. Ensuring resilient supply chains through diversified suppliers and regions will be pivotal for BMS and its partners.
Key Takeaways
- LUPKYNIS’s supply chain hinges on complex synthesis processes requiring high-purity intermediates sourced from specialized chemical suppliers.
- Bristol-Myers Squibb remains the primary producer of voclosporin but relies on an ecosystem of CMOs, predominantly in India and China, for scalability.
- Supply chain vulnerabilities include geopolitical risks, raw material shortages, and regulatory compliance; diversification and strategic partnerships mitigate these.
- Ongoing investments in manufacturing capacity and process innovation aim to improve supply resilience amid rising global demand.
- Transparency, ethical sourcing, and regulatory adherence are critical for maintaining uninterrupted supply and securing market confidence.
FAQs
1. Who are the main API suppliers for LUPKYNIS (voclosporin)?
Bristol-Myers Squibb primarily manufactures voclosporin internally but also collaborates with CMOs in regions like India and China for large-scale production of the API and intermediates, ensuring supply continuity.
2. Are there any alternative sources for voclosporin’s raw materials?
While alternative sources exist for chemical intermediates, the complexity of voclosporin synthesis and strict regulatory standards mean only a select group of qualified suppliers are used. Diversification strategies are ongoing to minimize risks.
3. How does regulatory compliance affect suppliers of LUPKYNIS?
Suppliers must meet cGMP standards set by agencies like the FDA and EMA. This compliance ensures product quality, safety, and efficacy, influencing supplier qualification and ongoing audits.
4. What factors could disrupt the supply chain for LUPKYNIS?
Global geopolitical tensions, raw material shortages, manufacturing delays, or quality compliance issues could all impact supply. Companies mitigate these risks through diversification, strategic inventory, and technological advances.
5. What is the future outlook for LUPKYNIS supply chain security?
Investments in manufacturing capacity, technological innovation, and regional diversification are expected to enhance supply resilience. Increasing demand will also drive strategic partnerships and supply chain optimization.
References
- Bristol-Myers Squibb. (2022). Annual Report.
- Pharmaceutical Technology. (2021). API Supply Chains in the Biopharmaceuticals Sector.
- U.S. Food and Drug Administration. (2022). Guidance for Industry: cGMP for Small Molecule Drugs.
- Market Research Future. (2022). Global Lupus Nephritis Therapeutics Market.
- Chemical & Engineering News. (2021). Supply Chain Considerations for Specialty Pharmaceuticals.
Note: The information provided is based on current publicly available data, industry reports, and the typical supply chain practices for complex small-molecule drugs like LUPKYNIS.
More… ↓
